Sandoz Group AG (Sandoz Group AG) EV-to-Revenue : (As of May. 13, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Sandoz Group AG's enterprise value is $18,916 Mil. Sandoz Group AG does not have enough years/quarters to calculate its Revenue for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Sandoz Group AG's EV-to-Revenue at this moment.

The historical rank and industry rank for Sandoz Group AG's EV-to-Revenue or its related term are showing as below:

SDZNY' s EV-to-Revenue Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0
Current: 1.9

SDZNY's EV-to-Revenue is ranked better than
57.13% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 2.38 vs SDZNY: 1.90

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-13), Sandoz Group AG's stock price is $35.51. Sandoz Group AG does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate Sandoz Group AG's PS Ratio at this moment.

Sandoz Group AG EV-to-Revenue Historical Data

The historical data trend for Sandoz Group AG's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG EV-to-Revenue Chart

Sandoz Group AG Annual Data

Trend

Dec22

Dec23

EV-to-Revenue

1.73

Sandoz Group AG Quarterly Data
	Dec22	Dec23
EV-to-Revenue	-	-

Competitive Comparison of Sandoz Group AG's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sandoz Group AG's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's EV-to-Revenue falls into.

Sandoz Group AG EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Sandoz Group AG's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	18916.421	/
	=

Sandoz Group AG (OTCPK:SDZNY) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Sandoz Group AG's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	35.51	/
	=

Sandoz Group AG EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Sandoz Group AG (Sandoz Group AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

SDZXF:USA SDZz:UK D8Y0:Germany SDZ:Switzerland

Address

Forum 1, Novartis Campus, Basel, CHE, CH-4056

Website

https://www.sandoz.com

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024